We further analyzed PD-L1 expression on tumor-infiltrating immune cells in tumors by flow cytometry, which revealed a significantly increased CD45+ PD-L1+ population post BNT162b2-based cancer therapy (Supplementary Fig. S7g). The gene discussed is PTPRC; the disease is cancer.